85598-19-2

Upstream product

• 85598-18-1 N-(p-Toluenesulfonyl)-4-hydroxymethyl-7-methoxyindole 
• 98-59-9 p-toluenesulfonyl chloride 
• 85598-17-0 N-(p-Toluenesulfonyl)-4-formyl-7-methoxyindole 
• 85628-22-4 N,N-Dimethyl-2-(2-nitro-3-methoxy-6-cyanophenyl)ethenamine 
• 85598-14-7 2-Nitro-3-methyl-4-cyanoanisole 
• 85598-13-6 1-bromo-4-methoxy-2-methyl-3-nitro-benzene 
• 85598-15-8 4-Cyano-7-methoxyindole 
• 85598-16-9 4-Formyl-7-methoxyindole 
• 85598-12-5 4-bromo-3-methyl-2-nitro-phenol 
• 4920-77-8 3-methyl-2-nitrophenol 

Downstream Products

• 85598-20-5 1-(p-Toluenesulfonyl)-4-methoxy-4-indoleacetonitrile 

Relevant academic research and scientific papers

NOVEL HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION

The present invention relates to novel heterocyclic compounds of general formula (I) that are phosphodiesterase inhibitors (PDEs), in particular phosphodiesterase type 4 inhibitors. These novel PDEs are useful in the treatment of inflammatory diseases (such as asthma, COPD, allergic rhinitis, allergic conjunctivitis, respiratory distress syndrome, chronic bronchitis, nephritis, rheumatoid spondylitis, osteoarthritis, atopic dermatitis, eosinophilic granuloma, psoriasis, rheumatoid septic shock, ulcerative colitis, multiple sclerosis, chronic inflammation, Crohn's syndrome and central nervous system(CNS) disorders) as well as disorders or conditions generally characterized by or associated with an excessive secretion of TNF-α and Phosphodiesterase 4 (PDE IV).